Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
OSMF
MCID: ORL004
MIFTS: 56

Oral Submucous Fibrosis (OSMF)

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases, Smell/Taste diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Oral Submucous Fibrosis

About this section

MalaCards integrated aliases for Oral Submucous Fibrosis:

Name: Oral Submucous Fibrosis 12 73 20 58 54 44 15 17 70 32
Oral Submucosal Fibrosis, Including of Tongue 12 70
Osmf 20 58
Oral Cavity Submucous Fibrosis 12
Oral Submucosal Fibrosis 12

Characteristics:

Orphanet epidemiological data:

58
oral submucous fibrosis
Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Oral diseases Smell/Taste diseases
See all MalaCards categories (disease lists)
ICD10: 32 33


External Ids:

Disease Ontology 12 DOID:5773
ICD9CM 34 528.8
MeSH 44 D009914
NCIt 50 C34866
SNOMED-CT 67 32883009
ICD10 32 K13.5
ICD10 via Orphanet 33 K13.5
UMLS via Orphanet 71 C0029172
Orphanet 58 ORPHA357154
UMLS 70 C0029171 C0029172
Sources

Summaries for Oral Submucous Fibrosis

About this section
GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 357154 Definition Oral submucous fibrosis (OSMF) is a chronic, progressive disease that alters the fibroelasticity of the oral submucosa, prevalent in India and Southeast Asia but rare elsewhere, and characterized by burning and pain in the oral cavity, loss of gustatory sensation, the presence of blanched fibrous bands and stiffening of the oral mucosa and oro-pharynx (leading to trismus and a progressive reduction in mouth opening) and an increased risk of developing oral squamous cell cancer (3-19%). It is usually associated with the chewing of the areca nut (an ingredient in betel quid) but the exact etiology is unknown and there is currently no effective treatment.

MalaCards based summary : Oral Submucous Fibrosis, also known as oral submucosal fibrosis, including of tongue, is related to ankylosis and deficiency anemia, and has symptoms including oral manifestations An important gene associated with Oral Submucous Fibrosis is LOX (Lysyl Oxidase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Hydrocortisone and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include bone, tongue and skin, and related phenotypes are narrow mouth and cheilitis

Disease Ontology : 12 A mouth disease that is characterized by juxta-epithelial inflammatory reaction and progressive fibrosis of the submucosal tissues.

Wikipedia : 73 Oral submucous fibrosis is a chronic, complex, premalignant (1% transformation risk) condition of the... more...

Sources

Related Diseases for Oral Submucous Fibrosis

About this section

Diseases related to Oral Submucous Fibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 389)
# Related Disease Score Top Affiliating Genes
1 ankylosis 30.5 TNF TGFB1 HIF1A
2 deficiency anemia 30.3 TNF TIMP1 HIF1A GSTM1 ENG CYP1A1
3 oral cancer 30.3 TP53 PTGS2 MMP9 MMP2 GSTM1 CYP1A1
4 oral squamous cell carcinoma 30.3 VEGFA TP53 MMP9 MMP2 HIF1A CDH1
5 localized scleroderma 30.2 TNF TGFB1 COL1A1
6 bone resorption disease 30.2 TNF COL1A2 COL1A1
7 gastritis 30.0 TP53 TNF PTGS2 CDH1
8 gingivitis 30.0 TNF TIMP1 MMP9
9 squamous cell carcinoma 29.7 VEGFA TP53 PTGS2 MMP9 MMP2 HIF1A
10 interstitial lung disease 29.7 TNF TIMP1 TGFB1 MMP9
11 skin disease 29.3 VEGFA TP53 TNF LOX LORICRIN
12 periodontitis 29.3 TNF TIMP1 PTGS2 MMP9 MMP3 MMP2
13 fibrosis of extraocular muscles, congenital, 1 11.3
14 leukoplakia 10.9
15 oral leukoplakia 10.8
16 lichen planus 10.6
17 oral mucosa leukoplakia 10.6
18 iron metabolism disease 10.5
19 oral lichen planus 10.5
20 keratosis 10.5
21 leukoregulin 10.4 TGFB1 PTGS2
22 iron deficiency anemia 10.4
23 verrucous carcinoma 10.4
24 posttransplant acute limbic encephalitis 10.4
25 beryllium disease 10.3 TNF TGFB1
26 inflammatory bowel disease 25 10.3 TNF PTGS2
27 squamous cell papilloma 10.3
28 papilloma 10.3
29 hypoxia 10.3
30 exfoliation syndrome 10.3 MMP3 LOX GSTM1
31 ehlers-danlos/osteogenesis imperfecta syndrome 10.3 COL1A2 COL1A1
32 col1a1/2 osteogenesis imperfecta 10.3 COL1A2 COL1A1
33 epstein-barr virus-associated gastric carcinoma 10.3 TNF CDH1
34 scirrhous adenocarcinoma 10.3 COL1A2 CDH1
35 hypertrophic scars 10.3 TIMP1 TGFB1 MMP2
36 urinary tract obstruction 10.3 TGFB1 PTGS2 CDH1
37 high bone mass osteogenesis imperfecta 10.3 COL1A2 COL1A1
38 bursitis 10.3 TNF PTGS2 MMP3
39 chronic beryllium disease 10.2 TNF TGFB1
40 arthrochalasia ehlers-danlos syndrome 10.2 COL1A2 COL1A1
41 oculopharyngeal muscular dystrophy 10.2
42 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
43 vitamin b12 deficiency 10.2
44 systemic scleroderma 10.2
45 pemphigus 10.2
46 48,xyyy 10.2
47 dysphagia 10.2
48 larsen-like syndrome 10.2 COL1A2 COL1A1
49 intravascular papillary endothelial hyperplasia 10.2 VEGFA HIF1A
50 ureteral disease 10.2 TNF TGFB1 CDH1

Graphical network of the top 20 diseases related to Oral Submucous Fibrosis:



Diseases related to Oral Submucous Fibrosis
Sources

Symptoms & Phenotypes for Oral Submucous Fibrosis

About this section

Human phenotypes related to Oral Submucous Fibrosis:

58 31 (show all 7)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 narrow mouth 58 31 hallmark (90%) Very frequent (99-80%) HP:0000160
2 cheilitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100825
3 abnormality of the pharynx 58 31 hallmark (90%) Very frequent (99-80%) HP:0000600
4 flexion contracture 58 31 frequent (33%) Frequent (79-30%) HP:0001371
5 trismus 58 31 frequent (33%) Frequent (79-30%) HP:0000211
6 oropharyngeal squamous cell carcinoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0012182
7 abnormal oral cavity morphology 58 Very frequent (99-80%)

UMLS symptoms related to Oral Submucous Fibrosis:


oral manifestations

MGI Mouse Phenotypes related to Oral Submucous Fibrosis:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.44 CDH1 COL1A1 COL1A2 ENG HIF1A LOX
2 homeostasis/metabolism MP:0005376 10.43 CDH1 COL1A1 COL1A2 CYP1A1 ENG HIF1A
3 growth/size/body region MP:0005378 10.42 CDH1 COL1A1 COL1A2 CYP1A1 ENG HIF1A
4 hematopoietic system MP:0005397 10.41 COL1A1 COL1A2 CYP1A1 ENG HIF1A LOX
5 immune system MP:0005387 10.39 CDH1 COL1A1 COL1A2 CYP1A1 HIF1A LOX
6 mortality/aging MP:0010768 10.31 CDH1 COL1A1 COL1A2 CYP1A1 ENG HIF1A
7 digestive/alimentary MP:0005381 10.27 CDH1 COL1A1 ENG HIF1A MMP9 PTGS2
8 embryo MP:0005380 10.27 CDH1 COL1A1 ENG HIF1A LOX PTGS2
9 integument MP:0010771 10.27 CDH1 COL1A1 COL1A2 ENG HIF1A LOX
10 endocrine/exocrine gland MP:0005379 10.26 CDH1 COL1A1 CYP1A1 HIF1A PTGS2 TGFB1
11 craniofacial MP:0005382 10.24 COL1A1 ENG HIF1A LOX MMP2 TGFB1
12 limbs/digits/tail MP:0005371 10.18 COL1A1 COL1A2 ENG HIF1A LOX MMP9
13 muscle MP:0005369 10.18 COL1A1 COL1A2 ENG HIF1A LOX MMP2
14 neoplasm MP:0002006 10.15 CDH1 COL1A1 HIF1A LOX MMP2 MMP9
15 nervous system MP:0003631 10.1 COL1A1 COL1A2 ENG HIF1A MMP2 MMP3
16 liver/biliary system MP:0005370 10.06 COL1A1 CYP1A1 HIF1A PTGS2 TGFB1 TNF
17 normal MP:0002873 9.85 CDH1 COL1A1 COL1A2 CYP1A1 ENG HIF1A
18 no phenotypic analysis MP:0003012 9.8 CDH1 COL1A1 CYP1A1 PTGS2 TNF TP53
19 respiratory system MP:0005388 9.73 COL1A1 ENG HIF1A LOX MMP2 MMP9
20 skeleton MP:0005390 9.44 COL1A1 COL1A2 HIF1A LOX MMP2 MMP3
Sources

Drugs & Therapeutics for Oral Submucous Fibrosis

About this section

Drugs for Oral Submucous Fibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
2
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
3
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
4
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
5 Viscosupplements Phase 3
6 Adjuvants, Immunologic Phase 3
7 Antioxidants Phase 3
8 Protective Agents Phase 3
9 Hydrocortisone 17-butyrate 21-propionate Phase 3
10 Hydrocortisone hemisuccinate Phase 3
11 Immunologic Factors Phase 3
12 Anti-Inflammatory Agents Phase 3
13 Respiratory System Agents Phase 3
14 Anti-Asthmatic Agents Phase 3
15 Hormones Phase 3
16 Hormone Antagonists Phase 3
17 Betamethasone benzoate Phase 3
18 glucocorticoids Phase 3
19 Betamethasone-17,21-dipropionate Phase 3
20 Betamethasone sodium phosphate Phase 3
21 Nigella Phase 3
22 Betamethasone Valerate Phase 3 2152-44-5
23
Curcumin Approved, Experimental, Investigational Phase 2 458-37-7 969516
24
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
25
tannic acid Approved Phase 2 1401-55-4
26 Antirheumatic Agents Phase 2
27 Anti-Inflammatory Agents, Non-Steroidal Phase 2
28 Analgesics Phase 2
29 Analgesics, Non-Narcotic Phase 2
30
Ethanol Approved 64-17-5 702
31 Immunoglobulins
32 Antibodies
33 Autoantibodies

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Evaluation of Efficacy of Aloevera in the Treatment of Oral Submucous Fibrosis- A Clinical Study Completed NCT02714543 Phase 3 aloevera juice;Hydrocortisone;Hyaluronic Acid;antioxidant;aloevera gel
2 Comparison of Nigella Sativa Oil With Conventional Management on Clinical Outcomes in Oral Submucous Fibrosis Not yet recruiting NCT04476420 Phase 3 Betamethasone Valerate
3 Topical Application of Curcumin Incorporated in Orabase in OSMF Patients Unknown status NCT02645656 Phase 2 Curcumin Arm
4 Innovative Formulations of Curcumin & Its Comparative Efficacy in Management of Oral Submucous Fibrosis. Unknown status NCT03511261 Phase 2 10% Curcumin mucoadhesive gel;Curcumin capsules 500mg;5% curcumin mucoadhesive gel + Curcumin capsules 250 mg;Placebo capsule
5 Evaluation of Change in Mouth Opening in Oral Submucous Fibrosis Patients After Surgical Excision of Fibrous Bands Along With Bilateral Coronoidotomy and Surgical Defect Coverage by Single Stage Extended Nasolabial Flap Completed NCT02711046
6 Risk Assessment of Malignant Transformation in Oral Submucous Fibrosis Using Epithelial Mesenchymal Transition (EMT) Signatures in Tissue Samples and Saliva Completed NCT03732872
7 Development of an Oral Epithelial Dysplasia Informational Needs Questionnaire Completed NCT04153266
8 Evaluation of Auto Antibodies in Oral Sub Mucous Fibrosis - a Clinico-pathological Study Completed NCT03011086
9 THE HONG KONG ORAL CANCER EDUCATION AND SCREENING (HOCES) PROGRAM: REFINING DISEASE PREVENTION, RISK STRATIFICATION AND EARLY DETECTION Not yet recruiting NCT04487938

Search NIH Clinical Center for Oral Submucous Fibrosis

Cochrane evidence based reviews: oral submucous fibrosis

Sources

Genetic Tests for Oral Submucous Fibrosis

About this section
Sources

Anatomical Context for Oral Submucous Fibrosis

About this section

MalaCards organs/tissues related to Oral Submucous Fibrosis:

40
Bone, Tongue, Skin, Breast, Lung, Endothelial, Heart
Sources

Publications for Oral Submucous Fibrosis

About this section

Articles related to Oral Submucous Fibrosis:

(show top 50) (show all 1335)
# Title Authors PMID Year
1
Association between lysyl oxidase polymorphisms and oral submucous fibrosis in older male areca chewers. 54 61
18764858 2009
2
Expression of matrix metalloproteinases (MMP-1, MMP-2 and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in oral submucous fibrosis. 61 54
17217211 2006
3
Augmented mRNA expression of tissue inhibitor of metalloproteinase-1 in buccal mucosal fibroblasts by arecoline and safrole as a possible pathogenesis for oral submucous fibrosis. 61 54
12907213 2003
4
The upregulation of lysyl oxidase in oral submucous fibrosis and squamous cell carcinoma. 61 54
10426196 1999
5
Increased lysyl oxidase activity in fibroblasts cultured from oral submucous fibrosis associated with betel nut chewing in Taiwan. 54 61
8537914 1995
6
Arecoline enhances miR-21 to promote buccal mucosal fibroblasts activation. 61
33191095 2021
7
A clinicobiochemical evaluation of curcumin as gel and as buccal mucoadhesive patches in the management of oral submucous fibrosis. 61
33509742 2021
8
Carcinogenesis of Male Oral Submucous Fibrosis Alters Salivary Microbiomes. 61
33089709 2021
9
Is Coronoidectomy Superior to Coronoidotomy for Improving Maximum Incisal Opening in Patients With Oral Submucous Fibrosis? 61
33345813 2021
10
Oral submucous fibrosis transforming into squamous cell carcinoma: a prospective study over 31 years in mainland China. 61
32844258 2021
11
Human papillomavirus prevalence in oral potentially malignant disorders: Systematic review and meta-analysis. 61
32144837 2021
12
Oral submucous fibrosis in children: an alarming condition and challenges in management. 61
33758041 2021
13
Letter to the Editor: "Carcinogenesis of Male Oral Submucous Fibrosis Alters Salivary Microbiomes". 61
33655805 2021
14
Response to the Letter to the Editor: "Carcinogenesis of Male Oral Submucous Fibrosis Alters Salivary Microbiomes". 61
33655776 2021
15
Skewed Th17/Treg balance during progression and malignant transformation of oral submucous fibrosis. 61
33749974 2021
16
Oral microbiota alteration associated with oral cancer and areca chewing. 61
32649007 2021
17
Targeting lncRNA H19/miR-29b/COL1A1 Axis Impedes Myofibroblast Activities of Precancerous Oral Submucous Fibrosis. 61
33672311 2021
18
Genome-wide DNA methylation changes in oral submucous fibrosis. 61
33615634 2021
19
A Comparative Study to Evaluate Efficacy of Curcumin and Aloe Vera Gel along with Oral Physiotherapy in the Management of Oral Submucous Fibrosis: A Randomized Clinical Trial. 61
33576219 2021
20
Effect of botulinum toxin-A on pain and mouth opening following surgical intervention in oral submucous fibrosis - A controlled clinical trial. 61
33757688 2021
21
Exosome-derived long non-coding RNA ADAMTS9-AS2 suppresses progression of oral submucous fibrosis via AKT signalling pathway. 61
33345447 2021
22
The Role of Increased Connective Tissue Growth Factor in the Pathogenesis of Oral Submucous Fibrosis and its Malignant Transformation-An Immunohistochemical Study. 61
33544386 2021
23
Research Achievements of Oral Submucous Fibrosis: Progress and Prospect. 61
33791368 2021
24
Comparison between Efficacy of Combined Use of Hyaluronidise and Triamcinolone versus Hyaluronidise, Triamcinolone Acetonide and Oral Colchicine in the Treatment of Oral Submucous Fibrosis. 61
33397855 2021
25
Inhibition of lncRNA HOTTIP ameliorated myofibroblast activities and inflammatory cytokines in oral submucous fibrosis. 61
33504462 2021
26
Efficacy of Lycopene in the Treatment of Oral Submucous Fibrosis: A Meta-analysis of Randomized Controlled Trials. 61
33303091 2020
27
Epithelial Distribution of E-Cadherin, p63, and Mitotic Figures in ApoTome Images to Determine the Oncogenic Potentiality of Oral Submucous Fibrosis. 61
33050978 2020
28
What is the Optimal Reconstructive Option for Oral Submucous Fibrosis? A Systematic Review and Meta-analysis of Buccal Pad of Fat Versus Conventional Nasolabial and Extended Nasolabial Flap Versus Platysma Myocutaneous Flap. 61
33071494 2020
29
Efficacy of Prednisolone Mouthwash in Management of Grade III Oral Submucous Fibrosis: A Newer Drug Regimen. 61
33071501 2020
30
Arctigenin suppresses fibroblast activity and extracellular matrix deposition in hypertrophic scarring by reducing inflammation and oxidative stress. 61
33174021 2020
31
Betel-Nut Chewing Increases Difficulty in Tracheal Intubation. 61
33550770 2020
32
Role of Prophylactic Coronoidectomy in Oral Cancer Treatment: a Retrospective Cohort Study. 61
33299286 2020
33
Oxidative-protective effect of nuclear receptor coactivator 7 on arecoline-induced endothelial-to-mesenchymal transition. 61
32988808 2020
34
Egr-1 mediates low-dose arecoline induced human oral mucosa fibroblast proliferation via transactivation of Wnt5a expression. 61
33167868 2020
35
Arecoline suppresses epithelial cell viability by upregulating tropomyosin-1 through the transforming growth factor-β/Smad pathway. 61
33332205 2020
36
Use of artificial intelligence in diagnosis of head and neck precancerous and cancerous lesions: A systematic review. 61
32674040 2020
37
CD147 promotes proliferation and migration of oral cancer cells by inhibiting junctions between E-cadherin and β-catenin. 61
32740991 2020
38
Signaling pathways promoting epithelial mesenchymal transition in oral submucous fibrosis and oral squamous cell carcinoma. 61
32874377 2020
39
Surgical management of oral submucous fibrosis with "Seagull-nasolabial flap" combined with short-term oral pentoxifylline for preventing relapse. 61
31904528 2020
40
Medicinal treatment of oral submucous fibrosis: Why is research not still translated into actual practice? 61
33246853 2020
41
Localized peripheral autonomous neuropathy and dysfunctional myoepithelial cells: A novel hypothesis for xerostomia in oral submucous fibrosis. 61
32758865 2020
42
Hypothesizing the therapeutic potential of mesenchymal stem cells in oral submucous fibrosis. 61
33254511 2020
43
Diminishing reactive adipogenesis leads to disease progression of oral submucous fibrosis. 61
33254526 2020
44
Malignant transformation of oral submucous fibrosis: A systematic review and meta-analysis. 61
33205543 2020
45
Single nucleotide polymorphisms and serologic levels of hypoxia-inducible factor1 α and vascular endothelial growth factor are associated with increased risk of oral submucous fibrosis in gutka users among a North Indian population. 61
32981864 2020
46
DNA content abnormality in oral submucous fibrosis concomitant leukoplakia: A preliminary evaluation of the diagnostic and clinical implications. 61
32433822 2020
47
Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis. 61
32977151 2020
48
Genetic Susceptibility and Protein Expression of Extracellular Matrix Turnover-Related Genes in Oral Submucous Fibrosis. 61
33143101 2020
49
Photobiomodulation therapy inhibits oral submucous fibrosis in mice. 61
32391600 2020
50
Efficacy of lycopene in management of Oral Submucous Fibrosis- A systematic review and meta-analysis. 61
33072506 2020
Sources

Variations for Oral Submucous Fibrosis

About this section
Sources

Expression for Oral Submucous Fibrosis

About this section
Search GEO for disease gene expression data for Oral Submucous Fibrosis.
Sources

Pathways for Oral Submucous Fibrosis

About this section

Pathways related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.02 VEGFA TP53 TNF TIMP1 TGFB1 PTGS2
2
ERK Signaling 63
Show member pathways
 13.81 VEGFA TP53 TNF TIMP1 TGFB1 PTGS2
3
Cytokine Signaling in Immune system 65
Show member pathways
 13.33 VEGFA TP53 TNF TIMP1 TGFB1 PTGS2
4
Circadian entrainment 36
Show member pathways
 13.02 VEGFA TGFB1 MMP9 MMP2 COL1A2 COL1A1
5
PI3K-Akt signaling pathway 36
Show member pathways
 12.98 VEGFA TP53 TNF PTGS2 COL1A2 COL1A1
6
Pathways in cancer 36
12.81 VEGFA TP53 TGFB1 PTGS2 MMP9 MMP2
7
Endometrial cancer 36
Show member pathways
 12.79 VEGFA TP53 TGFB1 MMP9 MMP3 CDH1
8
Degradation of the extracellular matrix 65
Show member pathways
 12.71 TIMP1 TGFB1 MMP9 MMP3 MMP2 LOX
9
G-protein signaling Ras family GTPases in kinase cascades (scheme) 23
Show member pathways
 12.34 VEGFA TP53 TIMP1 MMP3 HIF1A COL1A1
10
IL-17 Family Signaling Pathways 64
Show member pathways
 12.33 TNF PTGS2 MMP9 MMP3
11
Fluid shear stress and atherosclerosis 36
12.13 VEGFA TP53 TNF MMP9 MMP2 GSTM1
12
Proteoglycans in cancer 36
12.12 VEGFA TP53 TNF TGFB1 MMP9 MMP2
13
Colorectal Cancer Metastasis 63
12.08 VEGFA TP53 TNF TGFB1 PTGS2 MMP9
14
Adhesion 4
12.07 MMP9 MMP3 MMP2 COL1A1 CDH1
15
Spinal Cord Injury 1
12.05 TP53 TNF TGFB1 PTGS2 MMP9
16
TNF signaling pathway 36
11.97 TNF PTGS2 MMP9 MMP3
17
Matrix Metalloproteinases 1
Show member pathways
 11.95 TNF TIMP1 MMP9 MMP3 MMP2
18
AGE-RAGE signaling pathway in diabetic complications 36
11.93 VEGFA TNF TGFB1 MMP2 COL1A2 COL1A1
19
Amoebiasis 36
11.92 TNF TGFB1 COL1A2 COL1A1
20
Rheumatoid arthritis 36
11.87 VEGFA TNF TGFB1 MMP3
21
Bladder cancer 36 1
11.8 VEGFA TP53 MMP9 MMP2 CDH1
22
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.78 MMP9 MMP2 CDH1
23
C-MYB transcription factor network 1
11.77 PTGS2 GSTM1 COL1A2
24
Dendritic Cells Developmental Lineage Pathway 64
11.75 TNF TGFB1 CDH1
25
Lung fibrosis 1
11.72 TNF TIMP1 TGFB1 MMP9 MMP2
26
Renal cell carcinoma 36
11.71 VEGFA TGFB1 HIF1A
27
Transcription_P53 signaling pathway 23
11.7 VEGFA TP53 TGFB1 MMP2
28
AGE/RAGE pathway 1
11.69 MMP9 MMP2 HIF1A
29
HIF-1-alpha transcription factor network 1
11.68 VEGFA HIF1A ENG
30
Endochondral Ossification 1
11.67 VEGFA TGFB1 MMP9
31
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.64 VEGFA TNF PTGS2 MMP9 MMP3 MMP2
32
TGF-beta Receptor Signaling (WikiPathways) 1
11.62 TNF TGFB1 ENG
33
Celecoxib Pathway, Pharmacodynamics 60
11.62 VEGFA PTGS2 MMP9
34
Hepatitis C and Hepatocellular Carcinoma 1
11.6 VEGFA TP53 TGFB1 PTGS2 HIF1A
35
HIF1Alpha Pathway 63
11.58 VEGFA TP53 HIF1A
36
Cell adhesion_ECM remodeling 23
11.58 TIMP1 MMP9 MMP3 MMP2 COL1A2 COL1A1
37
Aryl Hydrocarbon Receptor 1
11.57 VEGFA TNF PTGS2 CYP1A1
38
Photodynamic therapy-induced AP-1 survival signaling. 1
11.55 TP53 TNF MMP2
39
Interleukin-10 signaling 65
11.52 TNF TIMP1 PTGS2
40
Aryl Hydrocarbon Receptor Pathway 1
11.51 TNF TGFB1 CYP1A1
41
amb2 Integrin signaling 1
11.51 TNF MMP9 MMP2
42
Angiogenesis (CST) 4
11.51 TIMP1 TGFB1 PTGS2 MMP9 MMP3 MMP2
43
Photodynamic therapy-induced HIF-1 survival signaling 1
11.44 VEGFA TP53 PTGS2 HIF1A
44
Interleukin-4 and 13 signaling 65
11.42 VEGFA TP53 TNF TIMP1 TGFB1 PTGS2
45
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.34 MMP9 MMP2 COL1A2
46
Development_Leptin signaling via JAK/STAT and MAPK cascades 23
Show member pathways
 11.28 VEGFA TIMP1 HIF1A
47
Angiogenesis (WikiPathways) 1
11.16 VEGFA MMP9 HIF1A
48
G-protein signaling_Rap2B regulation pathway 23
11.02 TNF TIMP1 TGFB1 COL1A2 COL1A1 CDH1
49
miR-148a/miR-31/FIH1/HIF1andalpha;-Notch signaling in glioblastoma 1
10.65 VEGFA HIF1A
Sources

GO Terms for Oral Submucous Fibrosis

About this section

Cellular components related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 VEGFA TNF TIMP1 TGFB1 MMP9 MMP3
2 collagen-containing extracellular matrix GO:0062023 9.77 TGFB1 MMP9 MMP2 COL1A2 COL1A1
3 extracellular space GO:0005615 9.7 VEGFA TNF TIMP1 TGFB1 MMP9 MMP3
4 platelet alpha granule lumen GO:0031093 9.58 VEGFA TIMP1 TGFB1
5 collagen trimer GO:0005581 9.56 TIMP1 LOX COL1A2 COL1A1
6 collagen type I trimer GO:0005584 9.32 COL1A2 COL1A1
7 extracellular matrix GO:0031012 9.28 VEGFA TIMP1 TGFB1 MMP9 MMP3 MMP2

Biological processes related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 10.19 TP53 TNF TGFB1 HIF1A COL1A1 CDH1
2 negative regulation of apoptotic process GO:0043066 10.13 VEGFA TP53 TIMP1 PTGS2 MMP9 HIF1A
3 positive regulation of gene expression GO:0010628 10.12 VEGFA TP53 TNF TGFB1 HIF1A ENG
4 positive regulation of apoptotic process GO:0043065 10.09 TP53 TNF TGFB1 PTGS2 MMP9
5 positive regulation of cell migration GO:0030335 10.04 VEGFA TGFB1 MMP9 COL1A1
6 negative regulation of gene expression GO:0010629 10.04 VEGFA TP53 TNF TGFB1 HIF1A ENG
7 heart development GO:0007507 10.03 TP53 TGFB1 LOX ENG
8 angiogenesis GO:0001525 10.03 VEGFA PTGS2 MMP2 HIF1A ENG
9 positive regulation of protein kinase B signaling GO:0051897 10.01 VEGFA TNF TGFB1 ENG
10 aging GO:0007568 10.01 TIMP1 TGFB1 PTGS2 CYP1A1
11 positive regulation of protein phosphorylation GO:0001934 10 VEGFA TNF TGFB1 MMP9 ENG
12 leukocyte migration GO:0050900 9.99 TNF TGFB1 MMP9 COL1A2 COL1A1
13 cellular response to hypoxia GO:0071456 9.96 VEGFA TP53 PTGS2 HIF1A
14 transforming growth factor beta receptor signaling pathway GO:0007179 9.94 TP53 TGFB1 ENG COL1A2
15 regulation of cell proliferation GO:0042127 9.93 TP53 TNF TGFB1 PTGS2 HIF1A ENG
16 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.92 TP53 TGFB1 ENG
17 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.91 VEGFA TNF TGFB1 PTGS2
18 cellular response to mechanical stimulus GO:0071260 9.91 TGFB1 PTGS2 ENG COL1A1
19 cellular response to organic cyclic compound GO:0071407 9.9 TNF TGFB1 CYP1A1
20 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.9 VEGFA TNF PTGS2
21 vasculogenesis GO:0001570 9.9 VEGFA TGFB1 ENG
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.9 TNF PTGS2 MMP2
23 positive regulation of MAP kinase activity GO:0043406 9.89 VEGFA TNF TGFB1
24 wound healing GO:0042060 9.89 TIMP1 TGFB1 LOX ENG COL1A1
25 blood vessel development GO:0001568 9.88 LOX HIF1A COL1A2 COL1A1
26 response to hypoxia GO:0001666 9.88 VEGFA TGFB1 MMP2 HIF1A ENG CYP1A1
27 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.87 TNF MMP9 MMP2
28 collagen fibril organization GO:0030199 9.87 LOX COL1A2 COL1A1
29 positive regulation of blood vessel endothelial cell migration GO:0043536 9.87 VEGFA TGFB1 HIF1A
30 bone mineralization GO:0030282 9.86 PTGS2 LOX COL1A2
31 positive regulation of protein complex assembly GO:0031334 9.86 VEGFA TNF TGFB1 MMP3
32 epithelial to mesenchymal transition GO:0001837 9.85 TGFB1 HIF1A ENG
33 positive regulation of protein import into nucleus GO:0042307 9.85 TGFB1 PTGS2 CDH1
34 collagen catabolic process GO:0030574 9.85 MMP9 MMP3 MMP2
35 protein kinase B signaling GO:0043491 9.85 TNF TGFB1 LOX
36 embryo implantation GO:0007566 9.84 PTGS2 MMP9 MMP2
37 negative regulation of mitotic cell cycle GO:0045930 9.84 TP53 TNF TGFB1
38 face morphogenesis GO:0060325 9.83 TGFB1 MMP2 COL1A1
39 cellular response to amino acid stimulus GO:0071230 9.83 TNF MMP2 COL1A2 COL1A1
40 positive regulation of vascular endothelial growth factor production GO:0010575 9.82 TGFB1 PTGS2 HIF1A
41 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.81 TP53 TNF TGFB1 HIF1A
42 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.8 TGFB1 LOX ENG
43 muscle cell cellular homeostasis GO:0046716 9.79 TGFB1 LOX HIF1A
44 extracellular matrix disassembly GO:0022617 9.77 TIMP1 MMP9 MMP3 MMP2 ENG
45 response to amyloid-beta GO:1904645 9.76 MMP9 MMP3 MMP2
46 response to drug GO:0042493 9.76 TP53 TGFB1 PTGS2 LOX ENG CYP1A1
47 extracellular matrix assembly GO:0085029 9.74 TGFB1 COL1A2
48 skin morphogenesis GO:0043589 9.74 COL1A2 COL1A1
49 positive regulation of vascular permeability GO:0043117 9.74 VEGFA TGFB1
50 response to salt stress GO:0009651 9.73 TP53 TNF

Molecular functions related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 10.14 TP53 TIMP1 PTGS2 MMP9 MMP3 MMP2
2 identical protein binding GO:0042802 9.81 VEGFA TP53 TNF TGFB1 MMP9 ENG
3 cytokine activity GO:0005125 9.67 VEGFA TNF TIMP1 TGFB1
4 platelet-derived growth factor binding GO:0048407 9.43 COL1A2 COL1A1
5 enzyme binding GO:0019899 9.43 TP53 TGFB1 PTGS2 HIF1A GSTM1 CYP1A1
6 type I transforming growth factor beta receptor binding GO:0034713 9.32 TGFB1 ENG
7 type II transforming growth factor beta receptor binding GO:0005114 9.26 TGFB1 ENG
8 protease binding GO:0002020 9.02 TP53 TNF TIMP1 COL1A2 COL1A1
Sources

Sources for Oral Submucous Fibrosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....